Skip to main
DCTH

Delcath Systems (DCTH) Stock Forecast & Price Target

Delcath Systems (DCTH) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Delcath Systems is an interventional oncology company focused on the treatment of primary and metastatic liver cancers, with a strong focus on their product, the Melphalan/HDS system. With a strong pipeline of new treatments and a growing network of active centers, the company is well-positioned for continued growth in the oncology market. Furthermore, Delcath's recent partnership with the National Cancer Institute and focus on strengthening its referral network indicates strong potential for future success.

Bears say

Delcath Systems is seeing growth in its product sales but at a slower rate than expected due to pricing pressures. With 340B pricing cutting effective ASP and limited volume growth, the company is facing challenges in increasing its revenue and profitability. However, the company's pipeline shows potential for future growth with ongoing trials for liver-dominant metastatic colorectal and breast cancer, but it may take time for results to materialize.

Delcath Systems (DCTH) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Delcath Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Delcath Systems (DCTH) Forecast

Analysts have given Delcath Systems (DCTH) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Delcath Systems (DCTH) has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Delcath Systems (DCTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.